Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
QMS Medical Allied Services Ltd

| Q4 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤9th Jun 26

Summary : QMS Medical Allied Services is transforming into a patient-centric healthcare solutions provider, making strategic investments to drive significant future growth in its high-margin service segment despite short-term profitability impacts.

Management Perspective positive : Management expressed optimism about future opportunities, confidence in doubling service revenue, and viewed current margin compression as strategic investment for long-term growth. They highlighted strong growth engines and market leadership.

Concall Report Analysis & Insights

Business Overview

  1. Evolved from medical device distribution to comprehensive healthcare solutions.
  2. Connects pharmaceutical companies, professionals, and patients across India.
  3. Serves over 130 institutional clients, reaching 5,000+ pin codes.
  4. Offers 900+ SKUs including medical devices, wellness products, and consumables.
  5. Provides services like screening camps, patient engagement, and disease management.

Future Growth Prospects

  1. Targeting to double service segment revenue in the coming year.
  2. Patient support programs (PSPs) are a significant growth engine.
  3. New GLP-1 drug therapies will boost patient engagement programs.
  4. Strategic investments in people, technology, and infrastructure will drive growth.
  5. Expanding leadership in the patient engagement ecosystem via Saarathi Healthcare.

Management Insights

  1. FY26 revenue grew 11% to INR172.9 crores, with strong long-term CAGR.
  2. Profitability impacted by strategic investments in people, technology, and infrastructure.
  3. Increased stake in Saarathi Healthcare to 76% to enhance service capabilities.
  4. Product segment contributed 69% of revenue, services 31% in FY26.
  5. Confident in service segment growth due to locked-in contracts and cost structure.

Signs of Skepticism

  1. Discrepancy in camp revenue numbers between presentation and management's statements.
  2. Analyst questioned the sustainability of revenue growth given H2 moderation.
  3. The impact of significant employee cost increase on future profitability needs monitoring.
  4. Management's claim of no direct competitors in their consolidated service space.

Risk Factors

  1. Product segment faced supply chain disruptions and order delays in H2 FY26.
  2. Short-term margin compression due to significant investments in services.
  3. Competitive landscape with online-only players disrupting pharma distribution.
  4. Reliance on pharma companies for program funding and patient identification.

Good To Know

  1. QMS is ISO certified and implementing DPDP Act compliance measures.
  2. Integrated technology platform serves over 1 million patients with real-time tracking.
  3. Patient support programs aim to improve treatment adherence and outcomes.
  4. Camps and patient service programs are funded by pharmaceutical companies.
  5. Service segment operates on per-camp, fixed-cost, and cost-plus models.

Key Drivers

  1. Doubling service segment revenue.
  2. Expansion of patient support programs.
  3. Impact from new GLP-1 drugs.
  4. Strategic investments in technology.

Key Analyst Discussions

Competitive Environment

  1. Management believes QMS is unique with its consolidated service offerings.
  2. Differentiated from online players like Practo by focusing on patient management.
  3. No other company has an all-India network for diverse health camps.
  4. Pharma companies increasingly seek QMS for patient support programs.

Market Trends & Consumer Behavior

  1. Patients often drop off medicine within the first month, leading to poor outcomes.
  2. Rising chronic diseases drive demand for structured patient support programs.
  3. Healthcare is shifting from product-focused to patient-focused engagement.
  4. Patient adherence and holistic treatment experience are crucial for pharma companies.

Financial Highlights

  1. Profit reduction despite revenue growth due to investments in software development.
  2. EBITDA margins for services are 25%, products 10-12%.
  3. H2 FY26 revenue moderated due to product segment disruptions.
  4. Employee costs increased significantly due to new hires for service expansion.

Product Composition

  1. Product segment contributed 69% of FY26 revenue, services 31%.
  2. Camps revenue expected to grow from INR13 crores to INR18-20 crores.
  3. Service segment includes camps, patient support programs, and education services.
  4. Camps are transactional, while patient service programs are long-term with fixed margins.

Strategic Considerations

  1. Saarathi Healthcare acquisition enhances capabilities in disease management.
  2. Humrahi and Jai platforms are key growth engines for patient services.
  3. Investments in people and technology are strategic for future service growth.
  4. Targeting to double service revenue by expanding programs and hiring staff.